Molecular Staging Molecular Staging is addressing this demand with a portfolio of products and services based on technologies that are transforming the detection and measurement of both proteins and nucleic acids.
  • Proteomics

    rcatschematic2

    If your scientific goals include biomarker discovery, validation, or assessing drug response, coverage is vital. MSI offers ultra-multiplexed protein analysis designed to yield a comprehensive look at the biology underlying disease and drug response.

    The MSI approach to proteomics

    The sequencing of the human genome has led to the
    identification of thousands of genes and proteins. Unlocking the potential
    value of these data depends upon defining the role genes and proteins
    play in disease and drug response. To date this process has been expensive,
    difficult and often constrains researchers to studying one protein at
    a time.

    The MSI approach to proteomics addresses these shortcomings with a systematic,
    highly parallel approach that enables researchers to study the expression
    of numerous proteins simultaneously.

    The MSI chip-based proteomics discovery platform, combined with sophisticated
    bioinformatics, offers researchers a powerful new way to identify new
    individual and multiplexed sets of biomarkers.

    This approach enables new insights into the biology underlying disease
    and drug response.

    RCATTM is uniquely able to amplify signals tethered to proteins,
    even low abundance proteins, with the thorough coverage required by today’s
    drug discovery and development.

    Researchers now have an efficient approach to several of today’s bottlenecks
    in drug discovery and development:

    • Disease classification
    • Drug triage
    • Patient stratification
    • Drug differentiation


    Advantages of RCAT
    for proteomics

    Expanded coverage
    Rather than studying only one protein at a time as in traditional assays,
    RCATTM enables researchers to study the expression of numerous
    biologically important proteins simultaneously. This expanded coverage
    promotes a deeper understanding of the biology underlying disease and
    drug response.

    Enhanced sensitivity
    Enhanced sensitivity offers scientists an unprecedented look at low-abundance
    proteins and the ability to evaluate the impact that subtle changes in
    protein expression will have on biology.

    Large dynamic range
    RCAT assays routinely exhibit ~3 logs of dynamic range. While conventional
    assays are limited in their ability to accurately quantify a particular
    protein in a sample, particularly if the amount differs significantly
    between samples, the expanded dynamic range of RCAT increases the understanding
    of protein expression differences in disease and drug response.

    Fast turnaround
    MSI proteomics chips used in RCAT assays have a sample-to-data collection
    turnaround time of less than four hours. This rapid turnaround facilitates
    high throughput and enables researchers to conduct short-time course studies
    and studies requiring iterative sample collection.

    Data reproducibility
    Leading the way in bioscience, the proteomics chips developed by MSI have
    routinely shown coefficients of variation (CVs) of less than 20%. Low
    CVs are essential when the goal is to perform large experiments over time
    and to generate meaningful, reproducible results.

    Hardware and software advantages

    RCAT works with a broad range of established instrument platforms. Studies
    using MSI proteomics chips can be conducted on off-the-shelf robots and
    array readers, taking full advantage of an installed equipment base. Data
    collection and analysis are done with a suite of proprietary software.

    Small samples and low reagent requirement
    Multiplexing and high sensitivity allow the evaluation of more proteins
    per unit of sample, reduced reagent usage, and reduced costs. This capability
    allows researchers to obtain a more comprehensive view of underling biology
    even when valuable sample is scarce.

    Lower overall costs
    The increased sensitivity of RCAT along with an expanded dynamic range
    and multiplexing result in higher throughput, higher quality results,
    and faster results with the use of smaller sample volumes and less reagent.
    These measures together result in lower overall discovery and development
    costs.

    Quantification
    Built-in calibration capability allows researchers to quantify expression
    levels and, in turn, to better assess biological relevance.

    Sampling-specific software flexibility
    MSI proteomics chips work equally well with serum, plasma, and supernatant,
    giving researchers the flexibility of choosing an assay format most appropriate
    for their specific research goals.

    Published on September 29, 2012 · Filed under: Bioscience, Diagnostics, DNA, Uncategorized; Tagged as:
    Comments Off on Proteomics